Literature DB >> 1707604

Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon.

M S Smith1, R J Thresher, J S Pagano.   

Abstract

Some murine retroviruses exhibit altered release of virus when cells are treated with alpha interferon (IFN-alpha), resulting in the accumulation of intracellular virions in cytoplasmic vacuoles. In studies of the inhibitory effect of IFN-alpha (Wellferon) on acute human immunodeficiency virus type 1 infection of human T-cell lines, we found that in C3 cells, the 50% effective concentration was 9 U/ml and the 90% effective concentration was 310 U/ml. There was no apparent accumulation of intracellular particles detected by p24 antigen levels or by processing the cells for electron microscopy. Extracellular reverse transcriptase activity and p24 levels decreased in parallel with increasing IFN, whereas the intracellular viral proteins decreased only slightly. By electron microscopy, cells treated with higher concentrations of IFN (512 U/ml) disclosed very few particles budding into extracellular spaces; no intracellular particles could be seen, despite nearly normal levels of intracellular viral protein detected by the p24 antigen assay and correct processing detected by Western blot (immunoblot) analysis. Thus in human immunodeficiency virus-infected cells, the major block produced by IFN-alpha appeared to be late in the viral cycle at the morphogenesis stage of virion production. Chronically infected Jurkat cells treated with IFN appeared to be inhibited in growth rate, as virus production decreased proportionally with cell number.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707604      PMCID: PMC244942          DOI: 10.1128/AAC.35.1.62

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2.

Authors:  J K Yamamoto; F Barré-Sinoussi; V Bolton; N C Pedersen; M B Gardner
Journal:  J Interferon Res       Date:  1986-04

2.  Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine.

Authors:  M S Smith; E L Brian; J S Pagano
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro.

Authors:  K L Hartshorn; D Neumeyer; M W Vogt; R T Schooley; M S Hirsch
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

5.  Two interferon sensitive steps in the replication cycle of Rous sarcoma virus.

Authors:  W Zens; H J Degen; A Barnekow; H Gelderblom; C Jungwirth
Journal:  Virology       Date:  1989-08       Impact factor: 3.616

6.  Functional role of human immunodeficiency virus type 1 vpu.

Authors:  E F Terwilliger; E A Cohen; Y C Lu; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

7.  Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines.

Authors:  G Poli; J M Orenstein; A Kinter; T M Folks; A S Fauci
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

8.  Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine.

Authors:  M S Smith; E L Brian; E De Clercq; J S Pagano
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

9.  Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1.

Authors:  M W Vogt; A G Durno; T C Chou; L A Coleman; T J Paradis; R T Schooley; J C Kaplan; M S Hirsch
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

10.  Ultrastructural comparison of the retroviruses associated with human and simian acquired immunodeficiency syndromes.

Authors:  R J Munn; P A Marx; J K Yamamoto; M B Gardner
Journal:  Lab Invest       Date:  1985-08       Impact factor: 5.662

View more
  21 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

2.  Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15.

Authors:  Atsushi Okumura; Gengshi Lu; Ian Pitha-Rowe; Paula M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-24       Impact factor: 11.205

3.  An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.

Authors:  Stuart J D Neil; Virginie Sandrin; Wesley I Sundquist; Paul D Bieniasz
Journal:  Cell Host Microbe       Date:  2007-09-13       Impact factor: 21.023

Review 4.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

5.  Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation.

Authors:  L A Pinto; V Blazevic; B K Patterson; C Mac Trubey; M J Dolan; G M Shearer
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Modulation of cytokine-induced HIV gene expression by competitive binding of transcription factors to the coactivator p300.

Authors:  M O Hottiger; L K Felzien; G J Nabel
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

7.  New insights on interactions between HIV-1 and HSV-2.

Authors:  Sinéad Delany-Moretlwe; Jairam R Lingappa; Connie Celum
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

8.  Evidence for a different susceptibility of primate lentiviruses to type I interferons.

Authors:  Stéphanie Cordeil; Xuan-Nhi Nguyen; Gregory Berger; Stéphanie Durand; Michelle Ainouze; Andrea Cimarelli
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 9.  Human immunodeficiency virus, restriction factors, and interferon.

Authors:  Stuart Neil; Paul Bieniasz
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

10.  Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer.

Authors:  Daniela Vendrame; Marion Sourisseau; Virginie Perrin; Olivier Schwartz; Fabrizio Mammano
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.